[HTML][HTML] Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial
L Gao, BW Lee, M Chawla, J Kim, L Huo, L Du… - Nature Medicine, 2023 - nature.com
Tirzepatide is a once-weekly GIP/GLP-1 receptor agonist. In this phase 3, randomized, open-
label trial, insulin-naive adults (≥ 18 years of age) with type 2 diabetes (T2D) uncontrolled …
label trial, insulin-naive adults (≥ 18 years of age) with type 2 diabetes (T2D) uncontrolled …
Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial.
L Gao, BW Lee, M Chawla, J Kim, L Huo, L Du… - Nature …, 2023 - europepmc.org
Tirzepatide is a once-weekly GIP/GLP-1 receptor agonist. In this phase 3, randomized, open-
label trial, insulin-naive adults (≥ 18 years of age) with type 2 diabetes (T2D) uncontrolled …
label trial, insulin-naive adults (≥ 18 years of age) with type 2 diabetes (T2D) uncontrolled …
Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial
L Gao, BW Lee, M Chawla, J Kim, L Huo, L Du… - 2023 - pubmed.ncbi.nlm.nih.gov
Tirzepatide is a once-weekly GIP/GLP-1 receptor agonist. In this phase 3, randomized, open-
label trial, insulin-naive adults (≥ 18 years of age) with type 2 diabetes (T2D) uncontrolled …
label trial, insulin-naive adults (≥ 18 years of age) with type 2 diabetes (T2D) uncontrolled …
Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial
L Gao, BW Lee, M Chawla, J Kim, L Huo… - Nature …, 2023 - yonsei.elsevierpure.com
Tirzepatide is a once-weekly GIP/GLP-1 receptor agonist. In this phase 3, randomized, open-
label trial, insulin-naive adults (≥ 18 years of age) with type 2 diabetes (T2D) uncontrolled …
label trial, insulin-naive adults (≥ 18 years of age) with type 2 diabetes (T2D) uncontrolled …
Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial
L Gao, BW Lee, M Chawla, J Kim, L Huo, L Du… - 2023 - ir.ymlib.yonsei.ac.kr
Tirzepatide is a once-weekly GIP/GLP-1 receptor agonist. In this phase 3, randomized, open-
label trial, insulin-naive adults (≥ 18 years of age) with type 2 diabetes (T2D) uncontrolled …
label trial, insulin-naive adults (≥ 18 years of age) with type 2 diabetes (T2D) uncontrolled …